Abstract Supportive care and pharmacological treatment can improve the quality of life of people with end-stage chronic obstructive pulmonary disease (COPD) who cope on a daily basis with substantial physical, psychological, social and spiritual morbidity. Smoking cessation is the only intervention that reduces the rate of progression of COPD, but evidencebased drug treatments and non-pharmacological strategies can relieve symptoms and reduce the impact of exacerbations. People with severe COPD live with increasingly troublesome breathlessness and other symptoms such as fatigue, pain, sputum production and weight loss. As breathlessness increases, treatment is stepped up from short-acting to longacting bronchodilators supplemented by non-pharmacological interventions such as pulmonary rehabilitation. Opiates relieve breathlessness, and referral to a multidisciplinary breathlessness service is an option for those with intractable symptoms. Other smoking-related conditions, such as coronary heart disease and lung cancer as well as depression and anxiety are common and should be treated with conventional pharmacotherapy. Acute exacerbations become more frequent and more severe as the disease reaches end-stage. Inhaled corticosteroids in combination with longacting bronchodilators can reduce the frequency of exacerbations, and supported self-management aims to facilitate timely treatment of deterioration. Palliative care services have traditionally been predicated on identifying people with endstage disease-a model that does not resonate with the unpredictable, relapsing trajectory of COPD. Approaches to care that promote a flexible approach to palliation alongside curative care could do much to improve the burden of living with severe COPD.
airflow obstruction [1] . It is predominantly caused by tobacco smoking, though cumulative exposure to occupational, indoor and outdoor air pollutants also contribute to the lung damage [2] . In many countries the burning of indoor biomass fuels is an important cause of COPD, with damage starting in infancy as young children are exposed to poorly ventilated cooking stoves [3, 4] .
Globally, COPD is a major cause of disability [5] . People with very severe COPD live, often for many years, with disabling physical symptoms (especially breathlessness), psychological distress and social isolation [6] [7] [8] [9] [10] . The holistic needs of these patients, however, are often poorly addressed [11] , with limited access to palliative care [12, 13] . Multi-morbidity is the norm, with at least 80% of people with COPD living with other long-term conditions, especially heart disease, depression and chronic pain [14] .
COPD is the third leading cause of death globally [15] . Exacerbations of COPD accelerate pulmonary damage, impair quality of life, increase morbidity and are a cause of premature mortality. Of those admitted to hospital in respiratory failure due to an acute exacerbation of COPD around half will die within 2 years (though conversely, of course, 50% will still be living with and needing support to manage their increasing disability) [16, 17] . Only about one-third of deaths are directly attributable to acute exacerbations of COPD; cardiovascular disease and cancer account for 27 and 21% of deaths, respectively [18] .
Concerns about inadequate services for patients with non-malignant diseases has led to calls to extend palliative care to all according to need rather than diagnosis [19] [20] [21] . The importance of adopting a supportive care approach in the care of people with advanced COPD is highlighted by international and national guidelines [1, [22] [23] [24] . This paper aims to provide an overview of the pharmacological treatment of people living with end-stage COPD within the broader context of palliative and supportive care.
Illness Trajectories and Palliative Care
Most models for provision of end-of-life care have evolved from palliative care services developed for people dying with cancer and are predicated on identifying people with end-stage disease, so that their physical, psychological, social and spiritual needs can be fully assessed and appropriate care planned. However, identifying a transition point at which palliative care becomes appropriate is not always easy in non-malignant conditions, and may be impossible in conditions with very long, unpredictable trajectories such as COPD [25] . Three different trajectories of physical decline have been described [19, 26] :
• People dying with cancer typically maintain their level of physical activity until late in the course of the disease, and the transition to a terminal phase when the focus switches from cure to palliation is (relatively) easy to identify.
• People with organ failure follow a pattern of slow physical deterioration punctuated by potentially serious exacerbations. The need for palliation of symptoms overlaps with active management of exacerbations with no clear-cut transition to an end-of-life phase [10] .
There is a risk of 'prognostic paralysis' if the lack of a transition point means that supportive care needs are not proactively addressed [27] .
• The frail elderly are characterised by prolonged 'dwindling', in which active treatment for multiple co-morbidities, palliation of long-term symptoms and supportive social care continue in parallel, potentially for many years.
Models of palliative care have adapted to address these different trajectories (see Fig. 1 ). Traditional models of care in which curative care gives way to palliative care (typically referral to hospice services) assume a clear transition point, and increasingly this is being replaced with models in which curative treatment overlaps with palliation [19, 26] . More recently, a flexible approach has been proposed in which palliation and supportive care are introduced early in the course of a potentially life-limiting condition, and are provided alongside curative treatments according to the fluctuating needs of a relapsing condition [28] .
Identifying People with COPD Who Have a Poor Prognosis
COPD has an insidious onset and an exceptionally long duration of disease, making it particularly difficult to give an accurate prognosis [29] . Patients struggle to identify when the symptoms started, adapt their lifestyles to cope with the gradually increasing disability and typically do not anticipate that the condition may be fatal [10, 30] . There are well-recognised indicators of a poor prognosis in COPD, including hospitalisation with an exacerbation, markers of severe disease, poor functional status, low body mass index, co-morbid heart disease or depression, and advanced age [16, 17, 31] . Despite these indicators, prognosis for many individual remains inaccurate [29] , and it has been suggested that a more helpful approach is for the clinician to ask themselves the question ''Would I be surprised if my patient were to die in the next 12 months?'' [26, 32] . The answer ''No, I would not be surprised'' should prompt consideration of the supportive and anticipatory care needs of the patient.
Recent guidelines have suggested that palliative careor at least a supportive care approach-should begin at the time of the diagnosis of a life-limiting illness such as COPD [1, 28] . This recognises that even in the earlier stages of the disease, palliation of symptoms is a key objective of treatment. A number of studies have observed that COPD patients even with advanced disease seem to be relatively undemanding [33] , accepting their breathlessness and general decline as inevitable or even 'normal' after a lifetime of smoking or exposure to other pollutants [10, 30, 34] , and do not seek help, believing that nothing can be done [34] . Early introduction of supportive care may help overcome this barrier to accepting care.
Improving Prognosis

Supporting Smoking Cessation
All patients with COPD (even those with severe disease) should be supported to stop smoking as smoking cessation benefits quality of life as well as reducing the rate of progression of COPD [35, 36] . Interventions should combine pharmacotherapy and behavioural support as this increases quit rates compared with a minimal intervention or usual care [37] , including specifically in people with COPD [38] . The impact on abstinence was similar in people with severe/very severe COPD as in those with more mild disease [38] .
An overview of pharmacological interventions for smoking cessation concluded that nicotine replacement therapy (NRT), varenicline (and combinations of NRT and varenicline), bupropion, cytosine and nortriptyline all increase the chances of quitting, with no increase in neuropsychiatric or cardiovascular events [39] . There is a small increased risk of seizures with bupropion.
All the available NRT preparations (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) increase the 6-month quit rate by between 50 and 70%, though combining a nicotine patch with a rapid delivery form of NRT is more effective than a single type of NRT [40] . Provision of NRT increases the effectiveness of counselling interventions in hospitalised patients [41] . Varenicline doubles abstinence at 6 months [42] , including in patients with COPD, in whom there was a reduction in respiratory symptoms and improved quality of life 1 year after randomisation [35] .
Long-Term Oxygen Therapy
Long-term oxygen therapy improves survival specifically in patients with chronic hypoxia [43, 44] , at least in the first 2 years [45] . It can improve sleep quality in people with sleep disturbance by correcting ventilation/perfusion mismatch due to nocturnal hypoventilation, though impact on quality of life is equivocal [46] . Use of long-term oxygen therapy for at least 15 h/day imposes considerable lifestyle restrictions [48, 51, 54] . Fig. 1 Models of care for people with life-threatening disease. Adapted with permission from Lynn and Adamson [19] and Lanken et al. [28] 4 Palliation of the Symptoms of Severe COPD The predominant symptom of COPD, responsible for causing major disability in people with severe disease, is breathlessness, although other symptoms such as fatigue, depression, cough, pain, confusion, anorexia and thirst may also be troublesome [6-9, 47, 48] . Careful attention to physical and psychological symptoms can reduce physical disability, increase concordance with treatment and relieve suffering [7, 49, 50] . Pharmacological management is summarised in Table 1 and described below.
Relieving Breathlessness
People with severe COPD report breathlessness all or most of the time [7, 9, 48, 51, 52] , using terms such as 'hard work', 'a constant struggle' and 'exhausting' to describe their symptoms [53] . Breathlessness is frightening for both patients and their carers [53] . Most patients with very severe disease need help with basic activities of daily living such as washing and dressing and preparing and eating food [51, 52, 54, 55] . Symptoms are of variable intensity with 'bad days' occurring unpredictably, making it difficult to plan activities or arrange social events [55] .
Relief of breathlessness is usually the first priority for palliative treatment for people with COPD. Echoing the pain ladder introduced in the context of cancer care, a 'dyspnoea ladder' (Fig. 2) has been suggested as an approach to effective management of breathlessness [8] , as described in Sects. 4.1.1-4.1.5.
Step 1: Short-Acting Bronchodilators as Required
Short-acting b 2 -agonists (SABAs) or short-acting muscarinic antagonists (SAMAs) should be the initial empirical treatment to relieve breathlessness and reduce exercise limitation [1, 56, 57] . Inhaler technique should always be checked before prescribing; very breathless patients with end-stage disease may find 'tidal breathing' with a metered-dose inhaler and spacer device the easiest option. In a few patients with distressing or disabling breathlessness despite maximal therapy, a trial of nebulised bronchodilator may be warranted [22] .
Step 2: Regular Long-Acting Bronchodilators
Most people with end-stage COPD will need treatment stepped up to regular use of long-acting b 2-agonists (LABAs) or long-acting anti-muscarinic agonists (LAMAs) [1] . Both LABAs and LAMAs reduce breathlessness, improve quality of life and reduce the frequency of exacerbations, though there is no evidence for a significant reduction in mortality or serious adverse events [58, 59] .
Inhaled Combination Therapies: A relatively recent innovation is the introduction of inhalers combining two long-acting bronchodilators (LABAs and LAMAs). This not only offers additional relief and improved quality of life [60] , but also simplifies the drug regimen with the aim of reducing poor adherence. Poor concordance with management advice is associated with increased exacerbations, hospitalisations, mortality and poor quality of life [61] .
Exacerbations become more frequent with more severe disease. In people who have frequent exacerbations (two or more exacerbations a year), LABAs (to relieve breathlessness) may be combined with inhaled corticosteroids (ICS) as this reduces exacerbation frequency [1, 23, 24, 62] , although there is an increased risk of pneumonia [63] . Finally, if breathlessness or frequent exacerbations remain troublesome, a LAMA can be used in addition (triple therapy) [64] .
Theophyllines: Theophyllines may have a small benefit in some patients but are limited by their adverse effects, especially in the context of co-existent cardiovascular disease [1] .
Step 3: Non-Pharmacological Measures
There are a number of non-pharmacological measures that can ease the sensation of breathlessness. Techniques such as pursed lip breathing, pacing activities and using a handheld fan to blow cool air on the face are all helpful strategies. Breathlessness engenders anxiety (in both patients and carers) and relaxation training may be considered.
Pulmonary rehabilitation is an important strategy for relieving breathlessness. It improves exercise capacity and health-related quality of life, reduces symptoms such as breathlessness, fatigue, anxiety and depression, enhances autonomy and reduces hospitalisation [65, 66] . Pulmonary rehabilitation should be offered to all symptomatic patients with COPD, irrespective of severity [67] . As well as exercise training, programmes address many of the features of living with advanced COPD, including assessment of functional capacity, education and self-management techniques, nutritional guidance, behavioural adaptation and psychosocial support [68, 69] . Access to local groups can provide the encouragement of peer support to help maintain activity levels (including recent evidence about the benefits of singing) [24, 70] .
Step 4: Opiates
If these measures are ineffective, opiates may be given orally, in low doses. A meta-analysis concluded that low- . These studies were generally small and not specifically in COPD, but the findings were corroborated by a more recent randomised, double-blind crossover study (n = 38; 88% had COPD), which confirmed that opiates reduced dyspnoea scores [72] . After 4 days on 20 mg of sustained-release morphine sulphate the mean improvement in the morning dyspnoea score compared with 4 days on placebo was 6.6 (95% confidence interval [CI] 1.6-11.6). Evening scores showed an even greater effect, with a mean improvement of 9.5 (95% CI 3.0-16.1).
The main adverse effect of opiates is constipation [72] Despite being given laxatives 'as needed', troublesome constipation occurred in about one-quarter of participants (n = 9) whilst taking morphine. Other adverse effects were nausea (n = 3) and sedation (n = 1). Fears about respiratory suppression appear to be unfounded. Nine of the trials in the systematic review measured the arterial partial pressure of oxygen (PaO 2 ); none reported a significant change [71] . Only one study reported a statistically, but not clinically, significant increase in the arterial partial pressure of carbon dioxide (PaCO 2 ) [71] .
Recommendations for the use of oral narcotics to relieve breathlessness suggest starting with a low dose (e.g. morphine 5 mg 4-hourly) [73] , titrating carefully to achieve the Figure 2 The dyspnoea ladder in severe chronic obstructive pulmonary disorder. Adapted from Rocker et al. [8] optimal effect balanced against troublesome adverse effects [1] .
In contrast, the effectiveness and safety of anxiolytics, such as diazepam or midazolam, is less clear [48, 74] . A Cochrane review concluded that benzodiazepines showed a trend towards a beneficial effect on breathlessness but this was non-significant [75] . This was recently confirmed in a recent crossover trial of intranasal midazolam [74] . Benzodiazepines, however, were less sedating than morphine so might be an option if the adverse effects of opiates preclude their use [75] or in the context of marked anxiety [76] .
In the absence of hypoxia, short-burst oxygen is not an effective treatment for breathlessness [77, 78] , with evidence that any perceived benefit may relate to the sensation of airflow across the face [76] . Oxygen guidelines recommend that patients with intractable breathlessness in endstage respiratory disease should not have oxygen therapy unless they are hypoxaemic [46] .
Step 5: Specialist Referral
There are several reasons for specialist referral. Non-invasive ventilation is being explored for people with very severe stable COPD but the evidence is insufficient to make clear recommendations [1, 79] . Surgical options (bullectomy, lung volume reduction, lung transplantation) can improve breathlessness in carefully selected patients [1] . There is growing interest in 'breathlessness services', which take a structured multidisciplinary approach to palliation of intractable dyspnoea in which optimisation of treatment is complemented by a positive educational approach for patients and their carers [80] .
Relieving Fatigue
Fatigue affects the day-to-day functioning of many people with severe COPD. It is associated with both increased breathlessness and depression and probably has both physical and psychological components [48] . Specific treatable causes such as hypoxia and anaemia should be excluded, but the best advice may be to 'pace' the activities of the day. Although not always feasible for housebound patients with very severe disease, pulmonary rehabilitation improves fatigue [66] .
Relieving Pain
Pain around the chest is a common but overlooked symptom of severe COPD [81] . People with severe airway obstruction have hyper-inflated lungs, and musculoskeletal pain may be the result of the effort of breathing at uncomfortable lung volumes, though other causes such as a pulmonary embolus or a chest infection should be considered. It may be possible to treat the underlying cause, and analgesia should be titrated up in a stepwise manner to achieve control [82] .
Addressing Weight Loss and Providing Nutritional Advice
Healthy, balanced nutrition is important in the management of COPD as both cachexia and obesity are prevalent. A low body mass index is an indicator of a poor prognosis [16] . Nutritional supplements can increase weight in malnourished people with COPD, and may have a small impact on exercise capacity and quality of life [83] . However, guidelines caution that the optimal amount and duration of supplementation is unclear [1] . On a practical level, advice about small frequent meals that require little chewing may help people overcome the difficulty of eating with severe breathlessness.
Relieving Chronic Sputum Production
A recent Cochrane review of airway clearance techniques (including postural drainage, breathing exercises, handheld positive expiratory pressure devices and high-frequency chest wall oscillation) to assist sputum clearance in patients with COPD and features of chronic bronchitis or bronchiectasis showed a reduction in hospital admissions, enhanced recovery post-exacerbation and improved healthrelated quality of life [84] . In people with chronic sputum production, mucolytics have a small beneficial effect on quality of life and reduce exacerbations compared with placebo by about one exacerbation every 3 years [85] .
Managing Multi-Morbidity
Multi-morbidity is the co-existence of two or more chronic conditions in the same individual [86] . In distinction to comorbidity (an additional ailment in a patient with a particular index disease [87] ), multi-morbidity does not presume an index condition; any of the co-existent conditions could be the most troublesome or significant at different points in time. Multi-morbidity is common, with most patients with severe COPD having between two and three additional long-term medical conditions [7, 14] . Other smoking-related illnesses such as coronary heart disease and lung cancer are particularly common, as are painful conditions such as osteoarthritis that may contribute to the adoption of an increasingly sedentary lifestyle.
The most recent update of the GOLD (Global Initiative for Chronic Obstructive Lung Disease) global guidelines offers recommendations on the management of COPD and co-morbidities [1] . The key recommendation is that the presence of co-morbidities should not change the management of the COPD and the presence of COPD should not alter the treatment of conditions such as ischaemic heart disease, heart failure, atrial fibrillation and hypertension (including prescribing of selective b 1 -blockers: bisoprolol is recommended). Systemic corticosteroids increase blood sugar, which may cause problems for people with diabetes mellitus, and frequent use of oral and/or high-dose ICS increases the risk of osteoporosis, which may require appropriate management.
However, the complexity of managing an elderly patient with COPD and (say) heart failure, diabetes, osteoporosis, mild cognitive impairment and poor vision exacerbated by limited social support extends beyond considering drug adverse effects and interactions [86] . Such situations require comprehensive assessment including use of STOPP/START (Screening Tool of Older Person's Prescriptions/Screening Tool to Alert doctors to Right Treatment) to rationalise treatment strategies [88, 89] . Specific interactions highlighted include the adverse effects of theophylline on cardiovascular morbidity and the risk of nebulised ipratropium in people with glaucoma. Case management may offer a holistic approach to ensure that all the important physical, psychological and social issues are addressed.
Depression and Anxiety
People with COPD are more than twice as likely to experience anxiety and depression than the general population, especially if they are hypoxic or have severe dyspnoea [90] . The prevalence of depression in patients with stable COPD may be as high as 42%, with anxiety in around 19% [91] . Panic attacks are common, affecting up to one-third of patients with COPD [92] . Depression has a significant effect on morbidity and mortality [93, 94] . People with depression are less likely to comply with treatment regimens, less likely to attend or complete a pulmonary rehabilitation course, and have more and longer hospital admissions.
The first step in managing anxiety and depression is to recognise that the problem exists. Patients found to be depressed or anxious should be treated with conventional pharmacotherapy. There is insufficient evidence to suggest that one class of anxiolytics or antidepressants is the preferred option, and the decision of which drug to prescribe may be determined by response to a trial of treatment and concern about potential adverse effects [95, 96] The presence of cardiovascular multi-morbidity, for example, may raise concerns about the safety of tricyclic antidepressants [88, 89, 97] Cognitive behavioural therapy [98, 99] and complex psychological interventions that include an exercise component [100] improve symptoms of depression and anxiety in people with COPD. If they can be supported to participate, even people with advanced disease may benefit from attending pulmonary rehabilitation, which has been shown to improve psychological morbidity [66] . A multidisciplinary approach to care, specifically including mental health professionals, may be helpful [101] . For patients with COPD and their carers, support groups may provide emotional support, social interaction, knowledge and advice on coping strategies.
Overlap with Asthma
Asthma and COPD are both common diseases and between 15 and 20% of people with COPD will have symptoms and variability suggestive of an asthma component [102] . From a management perspective, the key recommendation in patients with features of both asthma and COPD is to start by treating the asthma (with low/moderate ICS) and then add a LABA/ LAMA to relieve the ongoing breathlessness of COPD.
Preventing Exacerbations
An exacerbation of COPD is defined as an acute event characterised by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and which leads to a change in medication [1] . Exacerbations occur at any severity of COPD, but severe attacks requiring hospitalisation increase in frequency in people with endstage disease [103] . After assessment to identify the cause of the exacerbation, treatment includes increasing bronchodilation (SABA and/or SAMA with an easy-to-use inhaler device such as a spacer, or nebuliser in severe disease), oxygen (if hypoxic), oral corticosteroids (prednisolone 40 mg for 5 days), and antibacterials (if there is evidence of bacterial infection) [1] .
A key aim of the management of stable COPD is to prevent acute exacerbations. ICS given in combination with long-acting bronchodilators prevent one exacerbation every 2-4 years in a patient having one to two exacerbations a year [62] . ICS (combined with a LABA) should be considered for people with COPD who have two or more exacerbations a year [1] . The ICS dose used in COPD trials is moderate/high with the attendant risk of adverse effects (skin bruising, candidiasis and pneumonia, and concerns about osteoporosis).
The phosphodiesterase-4 inhibitor roflumilast reduces exacerbations in patients with severe to very severe COPD but causes more adverse effects than inhaled therapy [104, 105] . Despite some evidence that prophylactic antibacterials can reduce exacerbation frequency in people with severe COPD [106] , current guidelines do not recommend this approach because of the unfavourable balance between benefits and adverse effects [1] .
Annual influenza vaccination reduces the number of acute exacerbations and may reduce the number of hospitalisations and mortality related to COPD, and the pneumococcal vaccine reduces the incidence of invasive pneumococcal disease [107] .
Despite heterogeneity of interventions and inconsistent results, a recently updated Cochrane review concludes that, overall, supported self-management reduces admissions, reduces dyspnoea and improves quality of life [108] . People with severe COPD live with disabling symptoms and struggle to distinguish the early signs of exacerbations from 'bad days' [109] ; careful education and ongoing support is needed to ensure safe and effective self-management. The role of telehealthcare to support self-management is unclear, with inconsistent results [110] [111] [112] .
7 Psychosocial Morbidity and Advanced Care Planning
Psychosocial Support
The loss of mobility results in social isolation for both the patient and their spouse or carer [48, 54] . Even the simplest outing requires planning and can be frustrated at the last minute by a 'bad day' [113] . The need for regular medication, or to work within the constraints of ambulatory oxygen, may significantly limit activities. People become housebound not only because of their breathlessness but because their home is accessed by stairs or steep inclines or because they do not have basic mobility aids to enable them to go out [12] . Social isolation and a lack of contact with friends and family makes life feel 'meaningless' [113, 114] . Guidelines recommend that patients, their families and carers may benefit from the support of palliative care services [1] , but this is not always available and the reality is that families often cope with a significant burden of care with little support [6, 11, 34] .
Exacerbations, Prognosis and Advanced Care Planning
Despite initiatives to prevent admissions (such as selfmanagement, community support services, case management, 'Hospital at Home' care, telehealthcare), the majority of people with COPD die in hospital [50] . Some patients will have experienced non-invasive or invasive ventilation and may have clear views about how they wish future exacerbations to be managed, and these need to be explored and documented. Prioritising palliation of symptoms does not preclude acceptance of admission or ventilation should the need arise.
Clinicians often find it difficult to instigate discussions about future wishes of people with COPD [115, 116] , citing the unpredictable course of the disease as a barrier. Paradoxically, however, the unpredictability may also ease the discussion if it allows the hope that 'it may not happen to me yet'. Advanced planning can be presented as 'hoping for the best whilst preparing for the worst' [117] .
Conclusion
People with severe COPD live with significant physical, psychological, social and spiritual morbidity, but rarely have the holistic professional support and treatment that could improve their quality of life. The uncertain prognosis means that recognising those in need of a palliative care approach is difficult and it may be more helpful to consider palliation as running in parallel with the curative treatments. Evidence-based drug treatments and non-pharmacological strategies can improve outcomes, relieve symptoms and reduce the impact of exacerbations. Approaches to care that promote a flexible approach to palliation alongside curative care could do much to improve the burden of living with severe COPD.
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